Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Eledon Pharmaceuticals Inc
NASDAQ ELDN
Data sourced from
and
and
Eledon Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR for the year ending December 31, 2022
Eledon Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR is NA for the year ending December 31, 2022. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Eledon Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2022 was 8,821,425.01, a 125.70% change year over year.
-
Eledon Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2021 was -34,330,006.29, a -154.69% change year over year.
-
Eledon Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2020 was -13,479,271.94, a 0.52% change year over year.
-
Eledon Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the year ending December 31, 2019 was -13,550,029.98, a 3.52% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ELDN
| CEO | Dr. David-Alexandre C. Gros M.D., Ph.D. |
| IPO Date | Sept. 17, 2014 |
| Location | United States |
| Headquarters | 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 |
| Employees | 20 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
Acumen Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email